Compare · ABT vs HRMY
ABT vs HRMY
Side-by-side comparison of Abbott Laboratories (ABT) and Harmony Biosciences Holdings Inc. (HRMY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and HRMY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 81.3x HRMY ($2.23B).
- ABT has been more active in the news (13 items in the past 4 weeks vs 4 for HRMY).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Harmony Biosciences Holdings Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $2.23B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 13
- 4
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest HRMY
- Ladenburg Thalmann initiated coverage on Harmony Biosciences with a new price target
- SEC Form 8-K filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
- Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
- CHIEF MEDICAL OFFICER Budur Kumar exercised 38,452 shares at a strike of $30.40 and sold $1,655,416 worth of shares (38,452 units at $43.05) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF MEDICAL OFFICER Budur Kumar exercised 22,954 shares at a strike of $30.49 and sold $1,453,169 worth of shares (33,954 units at $42.80) as part of a pre-agreed trading plan, decreasing direct ownership by 46% to 13,115 units (SEC Form 4)
- Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
- Wolfe Research initiated coverage on Harmony Biosciences with a new price target
- Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
- SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.